LAUSR

Introduction The violation of the balance in the cytokine system is considered as an important mechanism for the development of cancer processes and ovarian cancer (OC). According to scientific confirmation, in the process of neogenesis occurs an imbalance between the production proneoplasticheskih (IL-6) and anti-neoplastic (IFN-γ, TNF-α) cytokines. Despite the improvement of diagnosis, OC treatment remains one of the urgent problems of oncogynecology. Material and methods The aim of the study was to evaluate the relations of the main cytokines of the immune system in patients with ovarian cancer stage II-III in the combined treatment on the background of immunotherapy. A total of 174 patients with stage T2–3N0 –1M0 OCwere examined and treated at oncogynecology and chemotherapy departments.Depending on the application of immunotherapy methods (EIPHT with the use of the thymus immunotropic drug (thymalin), EIPHT +PPh) in the combined PCT, the patients were divided into following groups: the 1st group - 32 practically healthy individuals; the 2nd group - 36 patients with OC before PCT; the 3rd group - 44 patients with OC after PCT without immunotherapy; the 4th group - 28 patients with OC after PCT combined with EIPHT; the 5th group - 34 patients with OC after PCT combined with EIPHT +PHh. Results and discussions Cytokines were studied by ELISA test (IL-6, IFN-γ, TNF-α) with the ‘Human’ test systems (Germany) in the dynamics of therapy. The following ratios of cytokines were studied: TNF-α/IL-6 and IFN-γ/IL-6.Normally, TNF-α/IL-6 is 0.69 and IFN-γ/IL-6 is 0.7.In the group of patients with ovarian cancer before treatment: TNF-α/IL-6–0.53, and IFN-γ/IL-6–0.58. In patients after chemotherapy without using immunotherapy: TNF-α/IL-6–0.59, and IFN-γ/IL-6–0.22. In the group of patients with combination of PCT and EIPHT: TNF-α/IL-6–0,66; IFN-γ/IL-6 1.46. In the group of patients withcombination of PCT and EIPHT+PHh: TNF-α/IL-6–0,97, and IFN-γ/IL-6–3,22.Consequently, in patients with OC before treatment and after PCT without immunotherapy, there is a pronounced imbalance of cytokines, which is aggravated by PCT. Conclusion The use of immunotherapy in combination with PCT is, in our opinion, a justified and effective method that leads to normalisation of immunological parameters of the immune system, allows improving immediate results of treatment, to reduce the intoxication caused by disease and makes it possible to carry out a ’full’ amount of therapy.